Use of Statins and Gallstone Risk

Hsu, Ching–Sheng; Kao, Jia‐Horng

doi:10.1001/jama.2010.320

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10][11][12][13][14] Therefore, there is a need for evidence evaluating the association between statin use and the occurrence of gallstone disease in an unselected population in general and in a US-based population in particular. 15,16 To address these limitations, we conducted a study using data from a large American military health care system (MHS) to evaluate the association between statin use and gallstone disease in a cohort of patients who were followed longitudinally for more than 8 years with similar access to care and complete follow-up.…”

Section: Introductionmentioning

confidence: 99%

Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures

et al. 2015

View full text Add to dashboard Cite

show abstract

Prior statin therapy is associated with milder course and better outcome in acute pancreatitis – A cohort study

et al. 2013

View full text Add to dashboard Cite

Long-term Statin Use and the Risk of Gallstone Disease: A Population-based Case-Control Study

Erichsen¹,

Frøslev²,

Lash³

et al. 2010

American Journal of Epidemiology

View full text Add to dashboard Cite

Most gallstones originate from cholesterol-supersaturated bile. Statins inhibit hepatic cholesterol biosynthesis and therefore may reduce the risk of gallstone disease. Population-based evidence, however, is sparse. Thus, the authors conducted a population-based case-control study using medical databases from northern Denmark (1.7 million inhabitants) to identify 32,494 cases of gallstones occurring between 1996 and 2008 and to identify age-, sex-, and county-matched population controls for each case. Cases and their matched controls who were exposed to lipid-lowering drugs were categorized as current users if their last prescription was redeemed ≤90 days before the case's diagnosis date; otherwise, they were categorized as former users. Conditional logistic regression was used to estimate adjusted odds ratios and 95% confidence intervals for gallstone disease in patients treated with lipid-lowering drugs. In current users, the adjusted odds ratios associating statin use with the occurrence of gallstone disease were 1.17 (95% confidence interval (CI): 1.06, 1.30) for those who had 1-4 prescriptions, 0.89 (95% CI: 0.80, 0.97) for those who had 5-19 prescriptions, and 0.76 (95% CI: 0.69, 0.84) for those who had ≥20 total prescriptions. In former users, the corresponding adjusted odds ratios were 1.24 (95% CI: 1.11, 1.39), 0.97 (95% CI: 0.86, 1.10), and 0.79 (95% CI: 0.64, 0.97), respectively. The use of other lipid-lowering drugs showed no similar association.

show abstract

Use of Statins and Gallstone Risk

Cited by 3 publications

References 9 publications

Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures

Association of Statin Therapy and Risks of Cholelithiasis, Biliary Tract Diseases, and Gallbladder Procedures

Prior statin therapy is associated with milder course and better outcome in acute pancreatitis – A cohort study

Long-term Statin Use and the Risk of Gallstone Disease: A Population-based Case-Control Study

Contact Info

Product

Resources

About